12:03 | 17/2/18
San Francisco Business Times
Arcus Biosciences Inc., launched by scientists after the $1.25 billion buyout of their previous company, hopes to raise $100 million in an initial public offering to pursue drugs that stimulate the immune system to attack cancer.
more»